 |
市场调查报告书
商品编码
1427257
ADME 毒理学测试全球市场规模、份额、成长分析、按技术、按应用划分 - 2023-2030 年产业预测Global ADME Toxicology Testing Market Size, Share, Growth Analysis, By Technology(Cell Culture, High Throughput), By Application(Systemic Toxicity, Renal Toxicity) - Industry Forecast 2023-2030 |
||||||
2022年全球ADME毒性测试市场规模预计为74.1亿美元，预测期内（2024-2031年）复合年增长率为11.5%，从2023年的82.6亿美元增至2031年的19.7亿美元。预计还将增长至 4000 万美元。
ADME毒性测试市场在评估物质的药物动力学和药物动力学方面发挥关键作用，提供对其吸收率、组织分布、代谢和排泄途径的重要见解。其主要目的是评估药物和化学品的潜在毒性和副作用，从而支持早期药物开发、临床前安全评估和风险管理。 ADME毒性测试市场成长的驱动力是对更安全、更有效的药物的需求不断增长。为了满足严格的监管要求和确保病人安全的需要，製药公司和研究人员依靠 ADME 研究来检查潜在毒性并预测候选药物的药物动力学特性。然而，由于人体生理学的复杂性和个体差异，ADME毒性测试市场面临挑战，这可能会影响测试结果和解释。此外，药物研发发现和开发的快速进步使得难以跟上不断变化的监管指南，并且需要不断努力来保持 ADME 测试方法的准确性和可靠性。综上所述，全球ADME毒性测试市场的重要目的是透过检查药物和化学品的药物动力学和毒代动力学来评估其安全性和有效性。对更安全药物的需求和合规性的需求推动了 ADME 毒性测试市场。儘管存在成本限制和寻找替代测试方法等挑战，但体外和电脑测试方法的进步以及个人化医疗的潜在应用正在出现机会。
自上而下和自下而上的方法已用于估计和检验全球 ADME 毒性测试市场的规模，并估计其他各个相关子市场的规模。用于估计市场规模的调查方法包括以下细节：透过二次研究确定市场中的主要企业，并透过主要和二次研究确定市场占有率。整个过程包括研究主要企业的年度和财务报告以及广泛的采访，以获得执行长、副总裁、董事和行销负责人等行业领导者的重要见解。所有股份比率和细分均使用二手资讯确定并使用主要资讯检验。本研究涵盖的所有影响市场的参数均经过初步研究进行检验和分析，以获得最终的定量和定性资料。
ADME 有毒测试全球市场細項分析
全球 ADME 毒理学测试市场根据技术、应用和区域进行细分。依技术划分，市场分为细胞培养、高通量、分子成像和体学技术。根据应用，市场分为全身性毒性、肾毒性、肝毒性、神经毒性等。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。
ADME 毒理学测试的全球市场驱动因素
2022年，在各种疾病的创新治疗方法需求的推动下，製药业的药物开发力度显着增加。对药物研发发现和药物开拓的日益重视在扩大 ADME 毒性测试市场方面发挥了至关重要的作用。製药公司和研究机构在进行临床试验和最终推向市场之前，严重依赖毒理学测试来彻底评估候选药物的安全性和有效性。
世界各地的监管机构推出了严格的指导方针，以确保药品的安全性和有效性。因此，ADME 毒性测试已成为监管评估过程的重要组成部分。遵守此类监管标准并获得核准的必要性成为 2022 年市场显着成长的有力催化剂。
全球ADME毒性测试市场的限制因素
与 ADME 毒性测试相关的成本可能很高，包括各种实验程序、专用设备和熟练劳动力。这一经济方面将成为 2022 年市场成长的阻碍因素，特别是影响预算有限的中小型製药公司。
关于动物福利的社会意识和道德考虑的提高正在刺激减少或取代毒理学研究中的动物测试的倡议。儘管开发和采用替代测试方法的潜力很大，但该行业在从传统动物模型过渡到这些新方法方面面临挑战。相关人员的目标是在确保准确的毒理学评估和尽量减少对动物测试的依赖之间取得平衡，这一限制将在 2022 年变得明显。
全球 ADME 毒理学测试市场趋势
2022 年，体外和电脑测试方法的进步显着加速。这些技术已成为传统动物实验的可行替代方案，为毒性评估提供了一种高效、经济且符合伦理道德的方法。试管内测定和预测建模技术的开发和采用的进步在提高毒理学预测的准确性和可靠性方面取得了重大突破。
FDA和欧洲药品管理局（EMA）等全球监管机构积极推动替代检测方法的考虑和引入。其总体目标是改善动物福利并提高毒性测试的可预测性和有效性。试管内测试、器官晶片等微生理系统和计算建模技术的发展势头正在推动这一变革趋势。公司正在投入资源进行研发，以创新和检验替代测试方法，为毒理学测试更道德和永续的发展做出贡献。
目录
- 执行摘要
- 调查方法
- 母市场分析
- 主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
- 市场动态及展望
- 市场动态
- 促进因素
- 机会
- 抑制因素
- 任务
- 监管形势
- 波特的分析
- 对未来中断的特殊考虑
- 市场动态
- 全球 ADME 毒理学测试市场：依技术分类
- 市场概况
- 细胞培养
- 高通量
- 分子影像
- 体学技术
- 全球 ADME 毒理学测试市场：按应用分类
- 市场概况
- 全身毒性
- 肾毒性
- 肝毒性
- 神经毒性
- 其他的
- 全球 ADME 毒性测试市场规模（按地区）
- 市场概况
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲地区
- 中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区
- 竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
- 主要企业简介
- Charles River Laboratories（US）
- Covance Inc.（US）
- Eurofins Scientific（Luxembourg）
- WuXi AppTec（China）
- Merck KGaA（Germany）
- Thermo Fisher Scientific（US）
- Cyprotex（UK）
- BioIVT（US）
- SGS SA（Switzerland）
- GE Healthcare（US）
- Promega Corporation（US）
- Absorption Systems（US）
- Catalent, Inc.（US）
- Lonza Group Ltd.（Switzerland）
- Evotec SE（Germany）
- Cyagen Biosciences（China）
- In Vitro ADMET Laboratories LLC（US）
- HD Biosciences（China）
- Sekisui XenoTech, LLC（US）
- Shanghai Medicilon Inc.（China）
Global ADME Toxicology Testing Market size was valued at USD 7.41 Billion in 2022 and is poised to grow from USD 8.26 Billion in 2023 to USD 19.74 Billion by 2031, at a CAGR of 11.5% during the forecast period (2024-2031).
The ADME toxicology testing market plays a crucial role in assessing the pharmacokinetics and toxicokinetic of substances, offering essential insights into their absorption rates, tissue distribution, metabolism, and elimination pathways. Its primary objective is to evaluate the potential toxicity and adverse effects of drugs and chemicals, thereby supporting early-stage drug development, preclinical safety assessments, and risk management. The driving force behind the growth of the ADME toxicology testing market is the escalating demand for safer and more effective drugs. In response to stringent regulatory requirements and the imperative to ensure patient safety, pharmaceutical companies and researchers rely on ADME testing to scrutinize the potential toxicity and anticipate the pharmacokinetic properties of their drug candidates. However, the ADME toxicology testing market faces challenges stemming from the intricacies of human physiology and individual variations, which can impact test outcomes and interpretations. Additionally, the rapid advancements in drug discovery and development pose difficulties in keeping pace with evolving regulatory guidelines, requiring constant efforts to uphold the accuracy and reliability of ADME testing methods. In essence, the global ADME toxicology testing market serves the crucial purpose of evaluating the safety and efficacy of drugs and chemicals by examining their pharmacokinetics and toxicokinetic. It is primarily fuelled by the demand for safer pharmaceuticals and the imperative of regulatory compliance. Despite challenges such as cost constraints and the exploration of alternative testing methods, opportunities emerge from advancements in in vitro and in silico testing approaches, along with the potential applications in personalized medicine.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global ADME Toxicology Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global ADME Toxicology Testing Market Segmental Analysis
The global ADME toxicology testing market is segmented on the basis of technology, application, and region. By Technology, the market is segmented into Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology. By Application, the market is segmented into Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global ADME Toxicology Testing Market
In 2022, the pharmaceutical industry witnessed a significant upswing in drug development initiatives, spurred by the demand for innovative therapies across various diseases. This intensified emphasis on drug discovery and development played a pivotal role in the expansion of the ADME toxicology testing market. Pharmaceutical companies and research institutions heavily relied on toxicology testing to meticulously evaluate the safety and effectiveness of their drug candidates before advancing to clinical trials and eventual market introduction.
Global regulatory authorities implemented stringent guidelines to ensure the robust assessment of safety and efficacy in pharmaceutical products. Consequently, ADME toxicology testing emerged as an indispensable element in the regulatory evaluation process. The imperative to adhere to these regulatory standards and secure approvals acted as a compelling catalyst for the substantial growth observed in the market throughout 2022.
Restraints in the Global ADME Toxicology Testing Market
The expenses associated with ADME toxicology testing can be substantial, encompassing various experimental procedures, specialized equipment, and a skilled workforce. This financial aspect acted as a hindrance to market growth in 2022, particularly impacting small and medium-sized pharmaceutical companies operating within constrained budgets.
Growing societal awareness and ethical considerations regarding animal welfare have stimulated initiatives to decrease or substitute animal testing in toxicology studies. While the potential of developing and adopting alternative testing methods is promising, the industry faced challenges in transitioning from traditional animal models to these newer approaches. This constraint was evident in 2022, as stakeholders aimed to strike a balance between ensuring precise toxicological assessments and minimizing reliance on animal experimentation.
Market Trends of the Global ADME Toxicology Testing Market
In 2022, there was a notable acceleration in the advancement of in vitro and in silico testing methods. These technologies emerged as viable alternatives to traditional animal testing, offering efficient, cost-effective, and ethically sound approaches to toxicology evaluation. The progress in developing and adopting in vitro assays and predictive modelling techniques marked a significant leap forward, enhancing the accuracy and reliability of toxicology predictions.
Global regulatory bodies, such as the FDA and the European Medicines Agency (EMA), actively promoted the exploration and incorporation of alternative testing methods. The overarching goal is to improve animal welfare and enhance the predictability and relevance of toxicity testing. The momentum in in vitro testing, micro physiological systems like organ-on-a-chip, and computational modelling techniques is steering this transformative trend. Companies are dedicating resources to research and development endeavours to innovate and validate alternative testing approaches, thereby contributing to the evolution of a more ethical and sustainable landscape for toxicology testing.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Market Dynamics
- Global ADME Toxicology Testing Market by Technology
- Market Overview
- Cell Culture
- High Throughput
- Molecular Imaging
- and OMICS Technology
- Global ADME Toxicology Testing Market by Application
- Market Overview
- Systemic Toxicity
- Renal Toxicity
- Hepatotoxicity
- Neurotoxicity
- and Others
- Global ADME Toxicology Testing Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Charles River Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Covance Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cyprotex (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioIVT (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SGS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promega Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Absorption Systems (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evotec SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cyagen Biosciences (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- In Vitro ADMET Laboratories LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- HD Biosciences (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sekisui XenoTech, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Medicilon Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories (US)
